Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease

PHASE3TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

August 3, 2022

Study Completion Date

August 3, 2022

Conditions
Autosomal Dominant Polycystic KidneyADPKD
Interventions
DRUG

Lixivaptan

Oral vasopressin V2 receptor antagonist

DRUG

Placebo

Matching placebo

Trial Locations (43)

1083

Semmelweis Egyetem, Budapest

2250

Renal Research - Gosford, Gosford

3200

Bugat Pal Korhaz, Gyöngyös

4001

University Multiprofile Hospital for Active Treatment - Kaspela, Plovdiv

4003

"Medical Center Hipokrat - N", Plovdiv

4032

Debreceni Egyetem, Debrecen

5809

University Multiprofile Hospital for Active Treatment, Pleven

6340

T.R. Ministry of Health Ankara Training and Research Hospital (Internal Disease, Division of Nephrology), Ankara

6500

Bajai Szent Rokus Korhaz, Baja

7622

University of Pecs, Pécs

8097

Hospital Universitari de Bellvitge (HUB), Barcelona

9000

Kidney Center - Medical Center, Varna

9002

Multi-Profile Hospital for Active Treatment Sveta Anna - Varna, Varna

18107

Northeast Clinical Research Center, LLC, Bethlehem

22033

Nephrology Associates of Northern Virginia, Inc, Fairfax

27560

Angel City Research, Inc, Morrisville

28040

Hospital Universitario Fundacion Jimenez Diaz, Madrid

32789

Clinical Site Partners, LLC, Winter Park

33010

Qway Research, Hialeah

33126

Total Research Group, LLC, Miami

33157

Innovation Medical Research Center, Inc, Palmetto Bay

33308

Elixia at Florida Kidney Physicians - Southeast, Fort Lauderdale

33462

JEM Research Institute, Atlantis

33615

Florida Kidney Physicians - Tampa, Tampa

34093

Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi, Fatih

34098

Istanbul Universitesi - Cerrahpasa Tip Fakultesi Hastanesi (IUCTFH), Fatih

35242

Nephrology Associates, PC - Greystone, Hoover

37923

Knoxville Kidney Center LLC, Knoxville

38039

Erciyes Universitesi Tip Fakultesi (Erciyes University Faculty of Medicine) (Internal Medicine; Nephrology), Kayseri

48066

St Clair Nephrology Research, LLC, Roseville

55905

Mayo Clinic, Rochester

64111

Clinical Research Consultants, LLC, Kansas City

78212

Clinical Advancement Center, PLLC, San Antonio

84115

Utah Kidney Research Institute, Salt Lake City

85258

Arizona Kidney Disease & Hypertension Center - Scottsdale / Pima, Scottsdale

35805-4104

Nephrology Consultants, LLC, Huntsville

33313-1600

South Florida Nephrology Associates PA, Lauderdale Lakes

02111

Tufts Medical Center, Inc,, Boston

02915-2235

Brown Medicine - Brown Physicians Patient Center, Riverside

77054-2854

Prolato Clinical Research Center (PCRC), Houston

31-559

SCM Spolka z o.o, Krakow

02-647

Provita Centrum Medyczne sp. z o.o., Warsaw

M6 8HD

Salford Royal NHS Foundation Trust, Salford

Sponsors
All Listed Sponsors
collaborator

Centessa Pharmaceuticals plc

INDUSTRY

lead

Palladio Biosciences

INDUSTRY

NCT04064346 - Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease | Biotech Hunter | Biotech Hunter